Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and safety of adding the once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone or together with metformin, in people with type 2 diabetes and elevated glycated hemoglobin (HbA1c). RESEARCH DESIGN AND METHODS: We conducted a double-blind, parallel-group, placebo-controlled trial. Patients (n = 495) with established basal insulin therapy but inadequate glycemic control were randomized to add lixisenatide 20 μg or placebo for 24 weeks. Basal insulin dosage was unchanged except to limit hypoglycemia. HbA1c reduction from baseline was the primary end point. RESULTS: Mean duration of diabetes was 12.5 years, duration of insulin use was 3.1 years, insulin dosage was 55 units/day, and baseline HbA1c was 8.4%. With lixisenatide, the placebo-corrected change of HbA1c from baseline was –0.4% (95% CI –0.6 to –0.2; P = 0.0002), and mean HbA1c at end point was 7.8%. HbA1c <7.0% (53 mmol/mol) was attained by more lixisenatide (28%) than placebo (12%; P < 0.0001) participants. Lixisenatide reduced plasma glucose levels after a standardized breakfast (placebo-corrected reduction, –3.8 mmol/L; P < 0.0001); seven-point glucose profiles showed a reduction persisting through the day. Reductions in body weight (placebo corrected, –1.3 kg; P < 0.0001) and insulin dosage (–3.7 units/day; P = 0.012) were greater with lixisenatide. Main adverse events (AEs) with lixisenatide were gastrointestinal. Symptomatic hypoglycemia was 28% for lixisenatide and 22% for placebo; 4 of 328 subjects (1.2%) had severe hypoglycemia with lixisenatide vs. 0 of 167 with placebo. CONCLUSIONS: By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin, lixisenatide may provide an alternative to rapid-acting insulin or other treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, the research of GetGoal-Duo1 and GetGoal-L also found that when the basic insulin treatment was not effective, the combination of LIXI could not only significantly improve fasting blood glucose and glycosylated hemoglobin but also significantly reduce weight, with the weight dropping by 0.9 kg and 1.3 kg respectively (71).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“However, slowing of gastric emptying appears to be greater with short-acting than with longacting GLP-1RAs (13), possibly related to the observation that, with time, continuous exposure of GLP-1 leads to a reduction in its effect on gastric emptying (14).”
Research works printed but not linked: 1
- Ratner, 2009, Post-meal pharmacodynamic profile of ACE0010, a once-daily GLP-1 receptor agonst, in patients with type 2 diabetes inadequally controlled on metformin, Diabetologia, 52, S60
Cited by
Items 201–288 of 288
Dril, E. V., Allison, M., & Schumacher, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100163 · Cited by 11
“The addition of a GLP-1 receptor agonist to basal insulin therapy consistently resulted in significant improvements in A1C in these studies [11 – 18], and most trials demonstrated similar rates of hypoglycemia [12 – 14 ,”
ResultA systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
Bergenstal, R. M., Strock, E. S., Mazze, R. S., Powers, M. A., Monk, A. M., Richter, S. A., Souhami, E., & Åhrén, B. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2879 · Cited by 8
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
The Impact of GLP-1 Receptor Agonists on Patients with Diabetes on Insulin Therapy
Gyorffy, J. B., Keithler, A. N., Wardian, J., Zarzabal, L. A., Rittel, A. G., & True, M. W. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0023 · Cited by 8
SKOLNIK, N., Hinnen, D., Kiriakov, Y., MAGWIRE, M. L., & White, J. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0048 · Cited by 9
“The addition of lixisenatide consistently improved A1C and PPG excursions, with body weight benefits and without an increase in hypoglycemia risk compared to basal insulin therapy alone (17,18).”
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Eto, K., Naito, Y., & Seino, Y. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0104-6 · Cited by 8
Shaefer, C. F. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.81 · Cited by 7
“Studies of lixisenatide in combination with basal insulin have shown promising results that seem to suggest an important role for lixisenatide in treating postprandial plasma glucose (25,26,29,38,39).”
Kim, J.-Y., Yang, S., Lee, J. I., & Chang, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153502 · Cited by 7
Seino, Y., Terauchi, Y., Wang, X., Watanabe, D., Niemoeller, E., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12646 · Cited by 7
Self-citationÅhrén, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30002-7 · Cited by 7
Bellido, D., Galiana, P. A., Palomar, J. M. R., Sintes, R. A., Nubiolae, A., Bellido, V., & Romero, G. Z. (2018) · Current Therapeutic Research · doi:10.1016/j.curtheres.2018.09.001 · Cited by 7
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
Davidson, J. A., Stager, W., Paranjape, S., Berria, R., & Leiter, L. A. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0088-5 · Cited by 6
“Methods: A post hoc pooled analysis was conducted using clinical trial data extracted from the intent-totreat subpopulation of patients with T2D who participated in the 24-week, phase 3, randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter GetGoal-L (NCT00715624), GetGoal-Duo 1 (NCT00975286)…”
BackgroundMethodInfluentialBaker, D. E., & Levien, T. L. (2017) · Hospital Pharmacy · doi:10.1310/hpj5201-65 · Cited by 6
Rajagopal, D., Rashid, S. A., Prasad, M., & Fareed, M. (2024) · Cureus · doi:10.7759/cureus.65910 · Cited by 12
“Studies have demonstrated that lixisenatide effectively enhances glycemic management and decreases elevated blood sugar levels after meals [15].”
BackgroundBroglio, F., Mannucci, E., Napoli, R., Nicolucci, A., Purrello, F., Nikonova, E., Stager, W., & Trevisan, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12810 · Cited by 6
Frías, J. P., Lorenz, M., Roberts, M., DEX, T. A., Schmider, W., Hurst, W., & SKOLNIK, N. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541316 · Cited by 6
Liu, F., Liu, Y., Liu, M., Wu, G., Zhang, M., Zhang, X., Cui, N., Yin, H., & Chen, L. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13504 · Cited by 7
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
Kitazawa, T., Yokoyama, K., & Kubota, K. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12423 · Cited by 6
Darmon, P., & Raccah, D. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30005-2 · Cited by 7
“GetGoal-L was a randomized controlled trial conducted to compare the efficacy and safety of adding lixisenatide 20 μg once daily vs placebo to previous basal insulin therapy administered alone or together with metformin in 495 patients with uncontrolled T2D [41].”
MethodGhosh, S. K., Unnikrishnan, A. G., Saboo, B., Kesavadev, J., Aravind, S. R., Bajaj, S., Rajput, R., Seshadri, K., Verma, N., Gupta, A., et al. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.045 · Cited by 7
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“However, clinical trials investigating GLP-1 RA combined with SU ( ± metformin) or insulin have found an increased incidence of hypoglycemia compared to placebo, although low [148].”
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
“20 Being a short-acting GLP-1RA analogue, lixisenatide lowers the PPG primarily by delaying gastric emptying markedly, although to a highly variable extent, depending on the baseline rate of gastric emptying.”
InfluentialYamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
Božek, T., Bilić-Čurčić, I., Berković, M. C., Gradišer, M., Kurir, T. T., Majanović, S. K., & Marušić, S. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0321-x · Cited by 5
“Our results indicate and confirm RCT data that lixisenatide add on basal insulin treatment can improve glycemic control in a population with long-standing type 2 diabetes and previously uncontrolled on other insulin therapeutic modalities.”
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Aronson, R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.842465 · Cited by 5
Self-citationMonnier, L., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30031-1 · Cited by 4
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Chen, M., Vider, E., & Plakogiannis, R. (2021) · Journal of Pharmacy Practice · doi:10.1177/0897190021993625 · Cited by 5
Otowa‐Suematsu, N., Sakaguchi, K., Nakamura, T., Hara, K., Kishi, M., Hashimoto, N., Yokota, K., Yoshino, H., Kuroki, Y., Nishiumi, T., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0505-2 · Cited by 4
Yabe, D., Iizuka, K., Baxter, M., Watanabe, D., & Kaneto, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13563 · Cited by 4
Seino, Y., Stjepanovic, A., Takami, A., Takagi, H., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12686 · Cited by 4
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
“…agreed also on the benefits of an intensification approach by adding GLP-1 RA to BI, in fixed or free combination, with the advantages of the extra-glycemic benefits of GLP-1 RA, as documented by several studies, such as the Get-Goal [41, 42], Lixilan [43–45] and Dual [46–50] clinical programs.”
DIGENIO, A. G., Karve, S. J., Candrilli, S. D., & Dalal, M. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2820 · Cited by 3
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
Self-citationWITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedLixisenatide: clinical profile and available evidence
Dicembrini, I., Bigiarini, M., & Mannucci, E. (2013) · Diabetes Management · doi:10.2217/dmt.13.64 · Cited by 3
Chan, W. B., Luk, A. O. Y., Chow, W. S., & Yeung, M. W. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12515 · Cited by 4
“001 for treatment difference, respectively).(56,57) Lixisenatide plus basal insulin has also been assessed in one study with an Asian population.”
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1029455 · Cited by 3
Shu, H., Gu, L., Men, L., & Lu, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0207-6 · Cited by 4
Fleischmann, H., Göke, R., & Bramlage, P. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.014 · Cited by 3
Harreiter, J., Kosi‐Trebotic, L., Lukas, A., Wolf, P. S., Winhofer, Y., Luger, A., Kautzky‐Willer, A., & Krebs, M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0249-4 · Cited by 3
“This small study corroborates recent findings of randomized controlled trials (RCTs) investigating the effects and safety of various combinations of once-daily Lixi with either iGlar compared to iGlar alone on top of metformin, or basal insulin compared to metformin and basal insulin, oral agents, or compared to place…”
SKOLNIK, N., Dupree, R. S., & Johnson, E. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1359518 · Cited by 3
Baker, D. E. (2017) · Hospital Pharmacy · doi:10.1177/0018578717715383 · Cited by 3
TRAUTMANN, M. E., & Vora, J. P. (2018) · Diabetic Medicine · doi:10.1111/dme.13610 · Cited by 3
Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3
Prasad, A., Arora, A., Arora, A., Vaid, J., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70515 · Cited by 3
Kruger, D. F., Isaacs, D. M., Hughes, L., Miller, E. M., & Bailey, T. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2331417 · Cited by 2
“Moreover, when addition of basal insulin is required, GLP-1 therapy often results in lower basal insulin dosages [19].”
Gautier, T., Silwal, R., & Breton, M. D. (2020) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2020.12.649 · Cited by 3
“The mixture has been shown to be safe and efficacious in the treatment of patients with T2DM Riddle MC (2013), Rosenstock J (2016).”
BackgroundInfluentialYao, J., Zhang, M., Zhang, X., & Zhang, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01369-6 · Cited by 2
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus
Forst, T. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1206079 · Cited by 2
“GI AEs were reported in 35–61% of patients in the lixisenatide arms [17–21] and in 15–20% of patients in the placebo arms of those trials whose design included a placebo arm [17,19,20], most of which were mild to moderate in intensity [20].”
Blonde, L., Bailey, T. S., Chao, J., DEX, T. A., Frías, J. P., Meneghini, L., Roberts, M., & Aroda, V. R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01033-1 · Cited by 2
Ding, N., Li, L., Zhu, X., Huang, X., Wang, L., & Yue, R. (2020) · Medicine · doi:10.1097/md.0000000000020343 · Cited by 2
Kaneto, H., Baxter, M., Takahashi, Y., & Terauchi, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02311-1 · Cited by 1
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Terauchi, Y., Naito, Y., & Ikeda, Y. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.08.008 · Cited by 1
Anholm, C., Frandsen, H., Sigfusson, E. C. H., Vestergaard, H., & Madsbad, S. (2014) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2014.42022 · Cited by 1
“7 U/day after 24 weeks of treatment [26].”
A new angle for glp-1 receptor agonist: the medical economics argument
Valencia, W. M., & Florez, H. J. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1069297 · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Juurinen, L. (2014) · Helda - University of Helsinki Institutional Repository
New pharmacological approaches to diabetes management
Eyadeh, A. A., & Jennings, P. E. (2015) · Practice Nursing · doi:10.12968/pnur.2015.26.3.140
Kurzzeitinsulin oder GLP-1-Analogon bei Typ-2-Diabetes?
Siegmund, T. (2014) · Info Diabetologie · doi:10.1007/s15034-014-0550-5
Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
Lyseng-Williamson, K. A., & Scott, L. J. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0059-3
“At week 24 in placebocontrolled trials, LSM changes from baseline in bodyweight were significantly better with lixisenatide than with placebo as add-on therapy to metformin [12], a sulfonylurea (±metformin) [15], basal insulin (±metformin) [17] and insulin glargine plus metformin (±a thiazolidinedione) [19].”
The place of IDegLira in the management of patients with Type 2 diabetes
Lansdown, A., Bain, S. C., & Chudleigh, R. A. (2015) · Diabetes Management · doi:10.2217/dmt.15.29
Pharmacologic Approach to Type 2 Diabetes in Obese Patients
Litwak, L., Musso, C., & Fuentes, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_10
Lixisenatide: A New Glucagon-Like Peptide-1 Agonist
Ho, C. W. (2013) · Journal of Developing Drugs · doi:10.4172/2329-6631.1000e134
“The Get Goal-L study randomized 496 participants in a 2:1 ratio to lixisenatide or placebo with or without the addition of metformin to the background of basal insulin therapy.”
InfluentialDiabète de type2: échec de l'insulinothérapie basale
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00014-6
Chapitre 15 – Diabète de type 2 : forte insulinorésistance
Monnier, L., RABASA-LHORET, R. P. R., & Colette, C. (2017)
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
Obeid, Y., Fadel, C., Sabra, N., & Tannous, J. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/7918
“No serious AEs were reported in Lixisenatide group, while four patients with at least one seriousAE in grouptwo, Table 8.”
InfluentialMen, P., Li, C., Zhai, S., & Qu, S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1662676
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Choudhary, A., Kannan, S. P., Parhi, K. K., & Jayagopalan, S. (2025) · International Journal of experimental research and review · doi:10.52756/ijerr.2025.v48.007
The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP ‐1 Agonists
Wani, S., Findakly, S., Phan, T. D., Lukies, M. W., Goh, G. S., Venn, G., Joseph, T., Koukounaras, J., & Clements, W. (2025) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70045
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Lipska, K. J., Zawack, K., Yan, L., Mutalik, P., Li, J., Gulanski, B., Ioannou, G. N., & Aslan, M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05216
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Metadata
- Authors
- Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Newcastle University (GB)
- Inserm (FR)
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Medical City Dallas Hospital (US)
- Corresponding author
- Riddle, Matthew C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2489-2496
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747925
- OpenAlex
- W2106709036
- Cited by
- 288
- References
- 29
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 32 · 2017: 41 · 2016: 36 · 2015: 44 · 2014: 39 · 2013: 20
- FWCI
- 36.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, type 2 diabetes, basal insulin, GLP-1 receptor agonists, glycemic control, HbA1c, postprandial hyperglycemia, hypoglycemia, weight loss, insulin dose reduction, metformin, gastrointestinal adverse effects, adjunctive therapy, glycemic variability, glycemic variability index
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.